337 related articles for article (PubMed ID: 26192590)
1. Selectivity Profiling and Biological Activity of Novel β-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Rüben K; Wurzlbauer A; Walte A; Sippl W; Bracher F; Becker W
PLoS One; 2015; 10(7):e0132453. PubMed ID: 26192590
[TBL] [Abstract][Full Text] [Related]
2. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
[TBL] [Abstract][Full Text] [Related]
3. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
[TBL] [Abstract][Full Text] [Related]
4. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Tarpley M; Oladapo HO; Strepay D; Caligan TB; Chdid L; Shehata H; Roques JR; Thomas R; Laudeman CP; Onyenwoke RU; Darr DB; Williams KP
Eur J Pharm Sci; 2021 Jul; 162():105821. PubMed ID: 33781856
[TBL] [Abstract][Full Text] [Related]
5. Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors.
Drung B; Scholz C; Barbosa VA; Nazari A; Sarragiotto MH; Schmidt B
Bioorg Med Chem Lett; 2014 Oct; 24(20):4854-60. PubMed ID: 25240617
[TBL] [Abstract][Full Text] [Related]
6. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
[TBL] [Abstract][Full Text] [Related]
7. Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
Darwish SS; Abdel-Halim M; ElHady AK; Salah M; Abadi AH; Becker W; Engel M
Eur J Med Chem; 2018 Oct; 158():270-285. PubMed ID: 30223116
[TBL] [Abstract][Full Text] [Related]
8. Activation, regulation, and inhibition of DYRK1A.
Becker W; Sippl W
FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
10. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
11. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.
Segretti ND; Takarada JE; Ferreira MA; da Silva Santiago A; Teodoro BVM; Damião MCFCB; Godoi PH; Cunha MR; Fala AM; Ramos PZ; Ishikawa EE; Mascarello A; Serafim RAM; Azevedo H; Guimarães CRW; Couñago RM
Bioorg Med Chem Lett; 2022 Jul; 68():128764. PubMed ID: 35504513
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of dual specificity kinase activity of DYRK1A.
Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
[TBL] [Abstract][Full Text] [Related]
14. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
[TBL] [Abstract][Full Text] [Related]
15. Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.
Kumar K; Man-Un Ung P; Wang P; Wang H; Li H; Andrews MK; Stewart AF; Schlessinger A; DeVita RJ
Eur J Med Chem; 2018 Sep; 157():1005-1016. PubMed ID: 30170319
[TBL] [Abstract][Full Text] [Related]
16. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.
Cuny GD; Ulyanova NP; Patnaik D; Liu JF; Lin X; Auerbach K; Ray SS; Xian J; Glicksman MA; Stein RL; Higgins JM
Bioorg Med Chem Lett; 2012 Mar; 22(5):2015-9. PubMed ID: 22335895
[TBL] [Abstract][Full Text] [Related]
18. Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts.
Grabher P; Durieu E; Kouloura E; Halabalaki M; Skaltsounis LA; Meijer L; Hamburger M; Potterat O
Planta Med; 2012 Jun; 78(10):951-6. PubMed ID: 22673832
[TBL] [Abstract][Full Text] [Related]
19. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.
Seifert A; Allan LA; Clarke PR
FEBS J; 2008 Dec; 275(24):6268-80. PubMed ID: 19016842
[TBL] [Abstract][Full Text] [Related]
20. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Mariano M; Hartmann RW; Engel M
Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]